Scientific Impact Recognition Award: Molecular breast imaging: A review of the Mayo Clinic experience

Hruska, Carrie B.; Boughey, Judy C.; Phillips, Stephen W.; Rhodes, Deborah J.; Wahner-Roedler, Dietlind L.; Whaley, Dana H.; Degnim, Amy C.; O'Connor, Michael K.

doi:10.1016/j.amjsurg.2008.06.005

« Previous Next »The American Journal of Surgery
Volume 196, Issue 4 , Pages 470-476, October 2008

Scientific Impact Recognition Award: Molecular breast imaging: A review of the Mayo Clinic experience

Carrie B. Hruska, M.D.
- Department of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
Judy C. Boughey, M.D.
- Department of Surgery, Mayo Clinic, Rochester, MN, USA
Stephen W. Phillips, M.D.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
Deborah J. Rhodes, M.D.
- Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, USA
Dietlind L. Wahner-Roedler, M.D.
- Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, USA
Dana H. Whaley, M.D.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
Amy C. Degnim, M.D.
- Department of Surgery, Mayo Clinic, Rochester, MN, USA
Michael K. O'Connor, Ph.D.
- Department of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
- Corresponding author. Tel.: +1-507-284-4399; fax: +1-507-266-4461

Received 16 April 2008; received in revised form 12 June 2008 published online 26 August 2008.

Abstract

Background

Molecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras.

Methods

MBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis.

Results

By using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter. Sensitivity improved to 91% (117 of 128) overall and 69% for tumors 5 mm or less using a dual-head system. In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography. In 24 of 149 (16%) breast cancer patients MBI detected additional disease not seen on mammography. The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ.

Conclusions

MBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma. It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning.

Keywords: Molecular breast imaging, Scintimammography, Breast cancer, Detection